Heartland Advisors Has Increased Its Intricon (IIN) Holding; Great Point Partners Trimmed Biocryst Pharmaceuticals (Call) (BCRX) Holding By $1.35 Million

September 3, 2017 - By Louis Casey

Heartland Advisors Inc increased Intricon Corp (IIN) stake by 35.6% reported in 2016Q4 SEC filing. Heartland Advisors Inc acquired 144,409 shares as Intricon Corp (IIN)’s stock rose 3.33%. The Heartland Advisors Inc holds 550,000 shares with $3.80M value, up from 405,591 last quarter. Intricon Corp now has $56.51 million valuation. The stock decreased 1.79% or $0.15 on September 1, reaching $8.25. About 6,876 shares traded. IntriCon Corporation (NASDAQ:IIN) has risen 44.30% since September 3, 2016 and is uptrending. It has outperformed by 27.60% the S&P500.

Great Point Partners Llc decreased Biocryst Pharmaceuticals (Call) (BCRX) stake by 31.03% reported in 2016Q4 SEC filing. Great Point Partners Llc sold 225,000 shares as Biocryst Pharmaceuticals (Call) (BCRX)’s stock declined 16.46%. The Great Point Partners Llc holds 500,000 shares with $3.17 million value, down from 725,000 last quarter. Biocryst Pharmaceuticals (Call) now has $402.14M valuation. The stock decreased 1.96% or $0.1 on September 1, reaching $5. About 755,786 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since September 3, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.

Investors sentiment increased to 1.6 in 2016 Q4. Its up 0.10, from 1.5 in 2016Q3. It improved, as 2 investors sold IIN shares while 6 reduced holdings. 2 funds opened positions while 5 raised stakes. 1.72 million shares or 6.20% more from 1.62 million shares in 2016Q3 were reported. California Pub Employees Retirement Sys invested in 34,116 shares. Bridgeway Management Incorporated stated it has 21,500 shares or 0% of all its holdings. Bard Associates Incorporated invested in 38,500 shares. New York-based Morgan Stanley has invested 0% in IntriCon Corporation (NASDAQ:IIN). Heartland Advsrs Inc holds 550,000 shares or 0.21% of its portfolio. Teton Advsrs Incorporated stated it has 178,617 shares. White Pine Capital Llc holds 0.05% or 17,800 shares. Northern Tru stated it has 0% of its portfolio in IntriCon Corporation (NASDAQ:IIN). Blackrock Institutional Tru Na holds 0% of its portfolio in IntriCon Corporation (NASDAQ:IIN) for 10,044 shares. Wells Fargo Mn reported 1 shares or 0% of all its holdings. Blackrock Ltd Liability has invested 0% in IntriCon Corporation (NASDAQ:IIN). Renaissance Technologies Limited Liability Company holds 174,400 shares or 0% of its portfolio. Blackrock Advsrs Ltd Liability reported 2,740 shares. Perritt stated it has 115,000 shares or 0.19% of all its holdings. National Bank Of America Corporation De accumulated 1,000 shares or 0% of the stock.

Heartland Advisors Inc decreased Carbo Ceramics Inc (NYSE:CRR) stake by 112,159 shares to 836,590 valued at $8.75 million in 2016Q4. It also reduced Heidrick & Struggles Intl In (NASDAQ:HSII) stake by 102,795 shares and now owns 704,709 shares. Tristate Cap Hldgs Inc (NASDAQ:TSC) was reduced too.

Among 3 analysts covering IntriCon (NASDAQ:IIN), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. IntriCon had 3 analyst reports since September 22, 2015 according to SRatingsIntel. The stock of IntriCon Corporation (NASDAQ:IIN) has “Sell” rating given on Tuesday, September 22 by Zacks. The rating was downgraded by Longbow on Friday, August 25 to “Neutral”. The stock of IntriCon Corporation (NASDAQ:IIN) earned “Buy” rating by Dougherty & Company on Friday, February 17.

Among 11 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. BioCryst Pharmaceuticals had 24 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Noble Financial on Friday, May 26 with “Buy”. The company was downgraded on Tuesday, February 9 by Jefferies. The firm has “Underperform” rating given on Wednesday, November 11 by Bank of America. The stock has “Buy” rating by Rodman & Renshaw on Tuesday, February 9. The rating was upgraded by PiperJaffray on Friday, August 12 to “Overweight”. As per Friday, August 12, the company rating was upgraded by Piperjaffray. The company was upgraded on Friday, December 16 by JMP Securities. The rating was downgraded by Needham on Tuesday, February 9 to “Hold”. The firm has “Buy” rating by H.C. Wainwright given on Friday, May 26. The rating was downgraded by Bank of America on Friday, October 9 to “Neutral”.

Great Point Partners Llc increased Sage Therapeutics Inc (NASDAQ:SAGE) stake by 120,790 shares to 385,683 valued at $19.69M in 2016Q4. It also upped Mirati Therapeutics Inc (NASDAQ:MRTX) stake by 642,604 shares and now owns 870,261 shares. Catabasis Pharmaceuticals Inc was raised too.

Since March 6, 2017, it had 0 insider purchases, and 3 selling transactions for $114,108 activity. $54,763 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares were sold by STAAB THOMAS R II.

Investors sentiment increased to 1.68 in 2016 Q4. Its up 0.18, from 1.5 in 2016Q3. It is positive, as 14 investors sold BCRX shares while 23 reduced holdings. 19 funds opened positions while 32 raised stakes. 52.04 million shares or 2.90% more from 50.57 million shares in 2016Q3 were reported. One Trading Ltd Partnership owns 81,176 shares or 0% of their US portfolio. Commonwealth Equity has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Metropolitan Life Ins New York reported 56,787 shares stake. National Planning Corporation stated it has 38,850 shares. Blackrock has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Quantitative Systematic Strategies Limited Liability Co holds 0.04% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 13,772 shares. Product Prtn Ltd Limited Liability Company holds 0.05% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) or 130,794 shares. Royal Bancorporation Of Canada owns 4,128 shares or 0% of their US portfolio. Comerica Fincl Bank invested in 0% or 16,105 shares. 966,854 are owned by Invesco Limited. Blackrock Institutional Trust Co Na owns 2.08 million shares. Tiaa Cref Management Ltd Liability Corp owns 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 360,022 shares. 45,913 were reported by Nationwide Fund Advsr. California Pub Employees Retirement reported 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 25,950 are owned by Creative Planning.